Press release from Companies

Publicerat: 2020-05-02 16:19:12

FluoGuide A/S: FluoGuide warrant TO 1 - last day of trading is Tuesday 5 May 2020

Tuesday, 5 May 2020, is the final day for trading in warrants of series TO 1 on Spotlight Stock Market. The Warrant TO 1 were issued in connection with FluoGuide A/S’s ("FluoGuide" or "the Company") IPO in 2019. The last day to subscribe for shares with the support of warrants of series TO 1 is 7 May 2020.

Warrants TO 1 that has not been subscribed for shares by Thursday 7 May 2020 or sold by Tuesday 5 May 2020 will expire and are thereafter worthless. The warrant holder needs to take action and instruct hers or his bank in due time, if not already done. It is solely the warrant holders’ responsibility.

Application forms are available for download on FluoGuide’s website (www.fluoguide.com), Sedermera Fondkommission’s website (sedermera.se) and Spotlight Stock Market’s website (spotlightstockmarket.com).

For further information regarding the warrants of series TO 1, please contact:
Sedermera Fondkommission
Phone: +46 40 - 615 14 10
E-mail: info@sedermera.se


For other information, please contact:

Morten Albrechtsen, CEO
M: +45 24 25 62 66


About FluoGuide 
FluoGuide A/S (Spotlight Stock Market: FLUO:SS) provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide’s first product FG001 increases precision in cancer surgery by lighting up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to reduce suffering for the patients and increase the likelihood of cure. It can also reduce costs for the health care system for the benefit of society. FluoGuide focuses on demonstrating the effect of FG001 in patients by conducting a human proof-of-concept clinical trial and expects to announce the first result of this study during first half of 2020.

About FG001
FG001, FluoGuide’s first product, lights up the cancer and its invasive growth into the surrounding tissue. It helps the surgeon remove the entire tumor during surgery and increases the chance for complete cure of the patient. The task for the surgeon is simply to "turn the lights on and see the entire tumor". The solution helps surgeons remove a minimal amount of normal tissue while also reducing the risk of leaving cancer tissue behind. This reduces the suffering of the patient and increases the likelihood of cure, and also reduces costs for the health care system. FG001 is currently prepared for a proof-of-concept clinical study.

Läs mer hos Cision
Läs mer om FluoGuide A/S